Impact of the risk-adapted Nordic anal cancer group consensus guidelines on the contouring of the elective clinical target volume in anal cancer
DOI:
https://doi.org/10.2340/1651-226X.2025.42723Keywords:
Anal carcinoma, Radiotherapy, Delineation, Contouring guidelines, Lymph node metastasisAbstract
Background and purpose: The recently published Nordic anal cancer group (NOAC) contouring guidelines aim for improved oncological outcomes and reduced toxicity in anal cancer patients treated with radiotherapy. The present work describes how the elective clinical target volume (CTVe) would change when applying the NOAC guidelines instead of the previous Australasian standard. According to the Australasian guidelines, the cranial border of the CTVe is at the common iliac bifurcation for all patients, and the external iliac region as well as the ischiorectal fossa are always included.
Materials and methods: Retrospectively, 166 anal cancer patients treated with curative radiotherapy according to Australasian guidelines between 2009 and 2017 were studied in a single-center analysis. Pretherapeutic scans, and clinical information were used to categorize patients according to the NOAC guidelines for a comparison with the Australasian guidelines.
Results: Applying the risk-adapted alternative of the NOAC guidelines had the external iliac region omitted in 41.0% of the patients. The cranial border was lowered from the common iliac bifurcation in 27.7% and elevated in 12.7% of the patients. Elderly patients (≥70 years) more often had the external iliac region omitted than younger patients (60.9% vs. 33.3%; p = 0.001). The entire ischiorectal fossa was included in 23.7% of the patients due to tumor extension beyond the levator ani muscles or external sphincter.
Interpretation: Contouring according to the NOAC risk-adapted guidelines changed, and mainly reduced, the CTVe in about half of all patients. Prospective follow-up is needed to determine if this is clinically beneficial.
Downloads
References
Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol. 2017;46(3):924–38.
https://doi.org/10.1093/ije/dyx200 DOI: https://doi.org/10.1093/ije/dyx200
Mignozzi S, Santucci C, Malvezzi M, Levi F, La Vecchia C, Negri E. Global trends in anal cancer incidence and mortality. Eur J Cancer Prev. 2024;33(2):77–86.
https://doi.org/10.1097/CEJ.0000000000000842 DOI: https://doi.org/10.1097/CEJ.0000000000000842
Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(¶). Ann Oncol. 2021;32(9):1087–100.
https://doi.org/10.1016/j.annonc.2021.06.015 DOI: https://doi.org/10.1016/j.annonc.2021.06.015
Johnsson A, Norman D, Angenete E, Cavalli-Björkman N, Lagerbäck C, Leon O, et al. Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results. Acta Oncol. 2022;61(5):575–82.
https://doi.org/10.1080/0284186X.2022.2048069 DOI: https://doi.org/10.1080/0284186X.2022.2048069
Ng M, Ho H, Skelton J, Guerrieri M, Guiney M, Chao M, et al. Intensity-modulated radiotherapy for anal cancer: dose-volume relationship of acute gastrointestinal toxicity and disease outcomes. Clin Oncol (R Coll Radiol). 2018;30(10):634–41.
https://doi.org/10.1016/j.clon.2018.07.020 DOI: https://doi.org/10.1016/j.clon.2018.07.020
Pan YB, Maeda Y, Wilson A, Glynne-Jones R, Vaizey CJ. Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review. Acta Oncol. 2018;57(11):1427–37.
https://doi.org/10.1080/0284186X.2018.1503713 DOI: https://doi.org/10.1080/0284186X.2018.1503713
Axelsson A, Johansson M, Haglind E, Li Y, Nilsson PJ, Angenete E. Patient reported long-term side effects on bowel function and anal pain in anal cancer survivors – 3- and 6-year results from the Swedish national ANCA study. Colorectal Dis. 2024;26(1):54–62.
https://doi.org/10.1111/codi.16814 DOI: https://doi.org/10.1111/codi.16814
Sterner A, Derwinger K, Staff C, Nilsson H, Angenete E. Quality of life in patients treated for anal carcinoma-a systematic literature review. Int J Colorectal Dis. 2019;34(9):1517–28.
https://doi.org/10.1007/s00384-019-03342-x DOI: https://doi.org/10.1007/s00384-019-03342-x
Nilsson MP, Gunnlaugsson A, Johnsson A, Scherman J. Dosimetric and clinical predictors for acute and late gastrointestinal toxicity following chemoradiotherapy of locally advanced anal cancer. Clin Oncol (R Coll Radiol). 2022;34(1):e35–e44.
https://doi.org/10.1016/j.clon.2021.09.011 DOI: https://doi.org/10.1016/j.clon.2021.09.011
Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009;93(2):298–301.
https://doi.org/10.1016/j.radonc.2009.07.006 DOI: https://doi.org/10.1016/j.radonc.2009.07.006
Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.
https://doi.org/10.1016/j.ijrobp.2012.09.023 DOI: https://doi.org/10.1016/j.ijrobp.2012.09.023
Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, et al. Long-term outcomes of NRG Oncology/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer. Int J Radiat Oncol Biol Phys. 2022;112(1):146–57.
https://doi.org/10.1016/j.ijrobp.2021.08.008 DOI: https://doi.org/10.1016/j.ijrobp.2021.08.008
Ludmir EB, Kachnic LA, Czito BG. Evolution and management of treatment-related toxicity in anal cancer. Surg Oncol Clin N Am. 2017;26(1):91–113.
https://doi.org/10.1016/j.soc.2016.07.004 DOI: https://doi.org/10.1016/j.soc.2016.07.004
Small W, Jr., Bosch WR, Harkenrider MM, Strauss JB, Abu-Rustum N, Albuquerque KV, et al. NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: an update. Int J Radiat Oncol Biol Phys. 2021;109(2):413–24.
https://doi.org/10.1016/j.ijrobp.2020.08.061 DOI: https://doi.org/10.1016/j.ijrobp.2020.08.061
Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 update. Radiother Oncol. 2019;134:1–9.
https://doi.org/10.1016/j.radonc.2019.01.018 DOI: https://doi.org/10.1016/j.radonc.2019.01.018
Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62.
https://doi.org/10.1016/j.ijrobp.2011.12.058 DOI: https://doi.org/10.1016/j.ijrobp.2011.12.058
Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824–30.
https://doi.org/10.1016/j.ijrobp.2008.08.070 DOI: https://doi.org/10.1016/j.ijrobp.2008.08.070
Nilsson MP, Undseth C, Albertsson P, Eidem M, Havelund BM, Johannsson J, et al. Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer. Acta Oncol. 2023;62(8):897–906.
https://doi.org/10.1080/0284186X.2023.2240490 DOI: https://doi.org/10.1080/0284186X.2023.2240490
Nilsson MP, Nilsson ED, Johnsson A, Leon O, Gunnlaugsson A, Scherman J. Patterns of recurrence in anal cancer: a detailed analysis. Radiat Oncol. 2020;15(1):125.
https://doi.org/10.1186/s13014-020-01567-7 DOI: https://doi.org/10.1186/s13014-020-01567-7
Frennered A, Scherman J, Buchwald P, Johnsson A, Sartor H, Zackrisson S, et al. Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes. BMC Cancer. 2021;21(1):447.
https://doi.org/10.1186/s12885-021-08187-8 DOI: https://doi.org/10.1186/s12885-021-08187-8
Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110.
https://doi.org/10.1007/s00259-017-3690-8 DOI: https://doi.org/10.1007/s00259-017-3690-8
Radiologists TRCo. National guidance for volumetric-modulated arc therapy (VMAT) or intensity-modulated radiotherapy (IMRT) in anal cancer. 2024, The Royal College of Radiologists, London.
Olsen JR, Moughan J, Myerson R, Abitbol A, Doncals DE, Johnson D, et al. Predictors of radiation therapy-related gastrointestinal toxicity from anal cancer dose-painted intensity modulated radiation therapy: secondary analysis of NRG oncology RTOG 0529. Int J Radiat Oncol Biol Phys. 2017;98(2):400–8.
https://doi.org/10.1016/j.ijrobp.2017.02.005 DOI: https://doi.org/10.1016/j.ijrobp.2017.02.005
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Marcus Johnsson, Sara Alkner, Anders Johnsson, Martin P. Nilsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
